Latest Auditor Review News

Mayne Pharma reports a robust first half of FY25 with revenues climbing to $210-$215 million and underlying EBITDA soaring by up to 300%, driven by strong performance in Women's Health.

PEXA Group Limited has updated its half-year guidance, flagging a $15 million non-cash impairment and a significant increase in tax expenses due to deferred tax asset derecognition.